Trial · NCT03430843
Adverse events408
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 408
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Tislelizumab | 80 | 255 | 139 |
| other | Anaemia | Blood and lymphatic system disorders | Investigator Chosen Chemotherapy (ICC) | 109 | 240 | 192 |
| other | Leukopenia | Blood and lymphatic system disorders | Tislelizumab | 9 | 255 | 19 |
| other | Leukopenia | Blood and lymphatic system disorders | Investigator Chosen Chemotherapy (ICC) | 29 | 240 | 57 |
| other | Neutropenia | Blood and lymphatic system disorders | Tislelizumab | 2 | 255 | 11 |
| other | Neutropenia | Blood and lymphatic system disorders | Investigator Chosen Chemotherapy (ICC) | 30 | 240 | 56 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Tislelizumab | 5 | 255 | 7 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Investigator Chosen Chemotherapy (ICC) | 10 | 240 | 13 |
| other | Hyperthyroidism | Endocrine disorders | Tislelizumab | 8 | 255 | 8 |
| other | Hyperthyroidism | Endocrine disorders | Investigator Chosen Chemotherapy (ICC) | 1 | 240 | 1 |
| other | Hypothyroidism | Endocrine disorders | Tislelizumab | 30 | 255 | 37 |
| other | Hypothyroidism | Endocrine disorders | Investigator Chosen Chemotherapy (ICC) | 1 | 240 | 1 |
| other | Abdominal distension | Gastrointestinal disorders | Tislelizumab | 9 | 255 | 10 |
| other | Abdominal distension | Gastrointestinal disorders | Investigator Chosen Chemotherapy (ICC) | 8 | 240 | 9 |
| other | Abdominal pain | Gastrointestinal disorders | Tislelizumab | 17 | 255 | 20 |
| other | Abdominal pain | Gastrointestinal disorders | Investigator Chosen Chemotherapy (ICC) | 22 | 240 | 27 |
| other | Abdominal pain upper | Gastrointestinal disorders | Tislelizumab | 9 | 255 | 12 |
| other | Abdominal pain upper | Gastrointestinal disorders | Investigator Chosen Chemotherapy (ICC) | 16 | 240 | 18 |
| other | Constipation | Gastrointestinal disorders | Tislelizumab | 41 | 255 | 46 |
| other | Constipation | Gastrointestinal disorders | Investigator Chosen Chemotherapy (ICC) | 45 | 240 | 60 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03430843/events